The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

Corne, Jonathan; Djukanović, Ratko; Thomas, Larry L.; Warner, J. O.; Botta, L.; Grandordy, B; Gygax, Daniel; Heusser, Christoph; Patalano, Francesco; Richardson, William H.; Kilchherr, Erich; Staehelin, Theophil; Davis, Frances M.; Gordon, Wayne L.; Sun, Lee K.; Liou, R. S.; Wang, G.; Chang, Tse Wen; Holgate, S. T.

doi:10.1172/jci119252

Cited by 159 publications

(72 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This leads to a marked decrease in levels of free IgE and a downregulation of cellular IgE receptors [14]. Single doses of omalizumab rapidly reduce free IgE concentrations by w95% in patients with allergic asthma [15][16][17].…”

mentioning

confidence: 99%

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Buhl¹,

Solèr²,

Matz³

et al. 2002

European Respiratory Journal

165

136

View full text Add to dashboard Cite

The ability of omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial.During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary.More omalizumab-treated patients (33.5%) than placebo-treated patients (13.5%) were able to complete the extension period without requiring inhaled corticosteroid treatment. The mean BDP equivalent dose throughout the extension was lower in the omalizumab group (25 mg?day -1 ) than in the placebo group (43 mg?day -1 ). Disease control was sustained in 76% of omalizumab patients compared with 59.4% of placebo patients free from an asthma exacerbation during the extension period. Compared with placebo, fewer patients in the omalizumab group used other concomitant asthma medication during the extension. Treatment with omalizumab was well tolerated and the incidence of adverse events was similar between groups.In conclusion, these results suggest that omalizumab is a promising new agent for the long-term control of allergic asthma. Eur Respir J 2002; 20: 73-78.

show abstract

mentioning

confidence: 99%

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Buhl¹,

Solèr²,

Matz³

et al. 2002

European Respiratory Journal

165

136

View full text Add to dashboard Cite

show abstract

“…pollens, dust mite allergen, molds). Proof-of-concept for an anti-IgE vaccine has already been established by clinical trials using passive immunization with non-anaphylactogenic anti-IgE monoclonal antibodies [19][20][21][22][23]. We have provided for a chemically-defined immunogen that elicits a polyclonal site-specific anti-IgE response.…”

Section: Discussionmentioning

confidence: 99%

“…These do not cross-link FcεRI-bound IgE and so they do not trigger degranulation and anaphylaxis [15,17,18]. Two of these antibodies are in clinical trial, and passive immunizations have provided desensitisation for patients with allergic rhinitis and allergic asthma [19][20][21][22][23]. An anti-IgE approach to immunotherapy by active immunization may have even greater promise than passive immunization due to cost effectiveness and potential for wider application.…”

Section: Introductionmentioning

confidence: 99%

Synthetic IgE peptide vaccine for immunotherapy of allergy

Wang¹

2003

Vaccine

View full text Add to dashboard Cite

“…The half-life of the drug was negatively correlated to the free baseline IgE levels. Also, the time for free IgE to return to baseline after anti-IgE treatment was negatively correlated with baseline IgE levels [15]. This issue may be summarized as higher IgE levels predict shorter half-life of anti-IgE antibody.…”

Section: Role Of Ige In Csumentioning

confidence: 99%

Anti IgE Therapy in Chronic Urticaria

Ertaş¹

2017

A Comprehensive Review of Urticaria and Angioedema

View full text Add to dashboard Cite

The crucial position of IgE within the pathogenesis of allergic diseases made it a key target for therapy. The inhibition of the allergic inlammatory cascade by anti-immunoglobulin E (IgE) therapy is a new and promising concept in the treatment of these diseases. Currently available anti-IgE agent omalizumab has been started to be used in past 3 years in the cases of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CINDU), resistant to the irst-, second-, and some third-line treatments. The use of omalizumab as an efective and safe biological therapy for inadequately controlled severe, persistent patients with CSU and CINDU provided a valuable new treatment option for these patients. However, the data about possible mechanisms of anti-IgE therapy in these patients, treatment strategies and dose regimens of anti-IgE therapy are diferent, and special patient groups and possible side efects are still insuicient. Also, studies about possible future anti-IgE treatment options are ongoing in CSU.

show abstract

The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

Cited by 159 publications

References 36 publications

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Synthetic IgE peptide vaccine for immunotherapy of allergy

Anti IgE Therapy in Chronic Urticaria

Contact Info

Product

Resources

About